Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Bladey, I’m kind of hoping some that took up the placing shares do flip them for a nice profit. This should allow a nice, steady consolidation of the sp rather than big spikes. We dont know what proportion of the shares went to ‘strategic’ IIs vs those who will just flip. Given the oversubscription I would say almost went to the former who should be in for the longer game than most on here.
This latest fall in the sp and subsequent placing has brought in new traders and investors. Any rises and consolidation will do the same. We need this to see long term growth in the sp. As you say it’s sensible to bank some profit so it will happen. However it’s those that continue to hold through all of the noise, even continuing to buy, that will reap huge rewards. Good luck on whatever your strategy is.
I am quite sure a few will be flipping after all it’s easy money. However, I suspect many more will see the value in holding and certainly some of the institutions will hold for the longer term. They will have done their DD before paying out £1.20 when the last placing was at 18p.
People don't get carried away with the ramping or deramping...stick to the facts.
Right now, the way i see it logically.. they've attained a goal of raising £45M.. which is a tantalising amount of money! I'll tell you now, if I had bought in the £1.20, depending on how many I could've bought.. I would flip a portion or all, how many people would do the same?..loads, people are looking out for themselves, simples!
Like I said before.. my biggest fear is the flipping of those shares when it's in their accounts! That will drag on the sp on top of the fact we STILL have the seller who is offloading. I was really hoping for an RNS this morning giving some positive progress with the collaboration tests... but nothing. Wait for Monday now? Results of some sort should have been issued by now.
Still not happy with the placing after it was promised there would be none, and now they've got the cash so they can take their sweet time. ...And please no feckin talk of II's have bought in, same happened in AAOG.. now it's a shell!
This is now 50/50 and we're in hope they'll release an update. I've already bagged from low 30's numerous times and traded twice so doing ok, but this is AIM..but fool me once!
Buy on the dips.... bank your profits ffs...always make sure you walk away with more than you invested!... try and aim for a free carry!
Trouble with your argument is that there's little detail to back it up.
Could I suggest you spend a few hours studying the work published by the Leeds group yesterday, linked here many posts ago. Then come back to us and tell us, in detail, why you think it doesn't work.
So I am surprised given the age of the company that no test in all that time has made it commercially
I'm thinking this is because they have approached affirmers has a lab product to provide to others to develop up until about 18 months ago. Since then have signed numerous deals in significant therapeutic space.
They have had some success inna couple of diagnostics but not to the point of commercialisation. This is why price is < £2 (plus their mates knew about placing) so the risks you describe are valid but possible built in to price.
Care share
do a little more in depth research
Gl
I've started seeing these types of comments as a flipside view now instead of a deramp after being proven wrong about no funding required.
Some good points made to be honest but not exactly true as of yet since those RNS's have yet to drop, true that none of us has actually seen this technology work and it could all be a hype train for them to put the business in the spotlight to secure funding for their core business.
BUT if you look at the history of the company spanning a few years ago and wayyy before any of this covid situation, you can see that they are and have been put in a situation where their technology has been primed for a situation like this, affirmers were i think suggested to them a few years back to be able to detect and confirm respratory diseases/infections, and i think we are all agreed that nobody in the world could have predicted Covid19 coming. Just thought id put abit of light onto that one
Secondly, yes you do have a point that their commercial partners are essentially shareholders and there may be conflict of interest, but thats just 1 distribution channel, the B2C. They still have to use the exact same product for B2B so why take the risk of losing 50% of an explosive cash-generating product just not to get it certified the right way?
Indeed the current marketcap based on the current financials do not align, but i think the biggest gains to make are from speculation because its only on markets like AIM where companies SPs will/can (as proven) multiply many times over in a day based off of one RNS.
There is no concrete product, there is no sales as of yet, there is no other distribution channels setup
But for those that have done their research, there is a 'transformational' set of results that are due in the coming weeks and IF those quell all the above mentioned question marks, then i guess we might have another AIM unicorn in the making
Totaly disagree with you there chap, no point exsplaing why your research is poor
Where is your evidence they don't work kev?
Sorry, but History will show this is a sham.
Avacta struggles to develop or commercialise anything, send out a couple of RNS about an unproven technology they call Affimers that have never been shown to work, and promise they will cure the world. Market Cap flies, and then they raise £48M, the vast majority of which is to fund the old core business that never worked either. When Affimers don’t work out, they won’t care. But is will be a long time until you hear that because it’s a self-declared CE mark, and the commercial partners (who also are AVACTAS shareholders) won’t let you know they don’t work. Unbelievable. Only AIM. The company should have much more solid evidence to justify this market cap - Many PIs going to get burned overnight when that RNS eventually comes out – or never comes out.
If you’re an investor that believes in the old core business, this has been an amazing windfall. If you’re investing for the COVID story, you’re in trouble IMO.